Roche Strikes Reality Note For Production Of Regeneron-Partnered COVID-19 Antibody Cocktail

Manufacturing A Massive Challenge

Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.

Roche_HQ
Roche has one of the largest bioreactor capacities in the world • Source: Archive

Roche Holding AG has high hopes for the investigational COVID-19 antibody cocktail from Regeneron Pharmaceuticals, Inc. it is helping to develop but Bill Anderson, head of pharma at the Swiss major, has warned that even if REGN-COV2 gets approval, demand will far outstrip supply.

REGN-COV2, a combination of two antibodies (REGN10933 and REGN10987) has been much in the news since doctors administered the treatment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip